Amylyx Pharmaceuticals, Inc. Common Stock (AMLX)
Market Closed
16 Oct, 08:00 PM
NASDAQ (NGS) NASDAQ (NGS) Primary $
26. 34
-1.31
-4.7378%
$
3.13B Market Cap
- P/E Ratio
- Div Yield
1.15M Volume
- Eps
$ 27.65
Previous Close 
Want to track AMLX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
This cheap biotech offers investors a play on ALS if trial data continues to impress
NeuroSense Therapeutics Ltd.'s stock rose 6.5% Tuesday, as analysts cheered data from the biotech's late-stage trial of a treatment for the fatal disease amyotrophic lateral sclerosis, or ALS.
Marketwatch | 2 years ago
Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar
Amylyx Pharmaceuticals has agreed to buy the rights to bankrupt drugmaker Eiger BioPharmaceuticals' experimental drug for low blood sugar in a $35.1 million deal, Eiger said in a filing on Friday.
Reuters | 2 years ago
2026 © Marketlog. All Rights Reserved.
